Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
The abundant presence of an enzyme known as low molecular weight protein tyrosine phosphatase (LMWPTP) in tumor cells has long been considered an indicator of cancer aggressiveness and metastatic potential.
CAR T cells are a breakthrough class of effective but often toxic cancer therapies. To prevent overactivation, switchable CAR T cells were engineered that can be turned on and off with an approved, widely used cancer drug.
Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers, according to new preclinical data from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center.
According to a new study, a novel T cell genetically engineered by scientists from The University of Arizona Health Sciences can target and attack pathogenic T cells that are responsible for causing Type 1 diabetes. These latest findings may result in new immunotherapy therapies.
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.
Clonal hematopoiesis (CH) is a recently identified condition in which mutations associated with blood cancers are detected in the blood of some healthy, usually older, individuals who don't have cancer. People with CH, while asymptomatic, have an elevated risk of developing blood cancers and other negative health outcomes, including heart attacks and strokes.
A phase 1 trial involving 12 children with relapsed neuroblastoma - a hard-to-treat pediatric cancer - shows that anticancer CAR T cells displayed signs of efficacy against these tumors while avoiding damage to nerve tissue.
Australian researchers have identified a protein that could protect the kidneys from 'bystander' damage caused by cancer therapies.
Scientists have identified possible means to prognosticate who will respond to cancer therapies that inhibit Wnt production.
In this interview, Dr. Shalin Naik speaks to AZoLifeSciences about his team's latest research that led to the discovery of a new step in the development of T and B cells that could help us to better understand leukemia.
A team of researchers from IDIBAPS-Hospital Clínic and the University of Barcelona has headed an international study to design an epigenetic clock that can track the amount of cancer cells that have multiplied previously.
University of North Carolina Lineberger Comprehensive Cancer Center researchers have identified a new and evolutionarily conserved pathway responsible for "closing down" gene activity in the mammalian cell.
A new study by scientists at UNC Lineberger Comprehensive Cancer Center and colleagues published Oct. 30, 2020, in Science, showed that mice exposed to potentially lethal levels of total body radiation were protected from radiation damage if they had specific types of bacteria in their gut.
In breakthrough colon cancer research, scientists at ChristianaCare's Helen F. Graham Cancer Center & Research Institute have discovered a link between two key signaling pathways crucial to the development and growth of colon cancer. The study is published today in the journal PLOS ONE.
Scientists have discovered that sodium bicarbonate - also known as baking soda or bicarbonate of soda - can reprogram T cells in leukemia patients to resist the immune-suppressing effects of cancer cells, which can drive leukemia relapse after stem cell transplants.
Scientists have shown that cancer rebuilds the architecture of human chromosomes, which allows the disease to take hold and spread.
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published today in Nature Communications.
Like people, cells in the human body protect their personal space. They seem to know how much space they need, and if it gets too tight, most cells prefer to break free.
The development of cancer is a highly complicated process, involving multiple genes and signaling pathways that become upregulated or downregulated throughout different stages of tumor growth and spread. Two of the most commonly altered genes in cancer are p53 and AKT.
Natural killer T (NKT) cells, a type of immune cells known for their potent anti-cancer properties in murine tumor models, have been developed into a novel form of immunotherapy to treat patients with cancer.